Diabetes mellitus by itself, is a frequent and increasing public health problem. The prevalence in most Western countries varies between 2 to 5% and it is rapidly increasing in Asiatic countries due to changes in dietary habits during the last years. The association between diabetes mellitus and hypertension has been described in 60 to 65% of diabetics. In hypertension we find insulin resistance mainly in skeletal muscle involving the conversion of glucose to glycogen independently of blood flow. The degree of resistance is related to the severity of hypertension and varies between races. States of
Introduction
Diabetes mellitus and hypertension coexist more frequently than reported in classic literature in studies of large populations of developed countries yielding values between 60 to 65% of coexistence. 1 It is also known that high blood pressure is two to three times more frequent in diabetic patients. These pathologies are independent risk factors for cardiovascular disease and when they coexist there is an increase of two to eight times in morbidity for cardiovascular disease and the mortality for those diseases is duplicated. 1, 2 The factors involved in this association include: (1) the frequency for both diseases increases with age; (2) they have the same predisposing factors; (3) hypertension is secondary to the diabetic complications, usually nephropathy in type 1 diabetes; (4) hypertension in type 2 diabetics could appear before, or could be related to, diabetic nephropathy.
Although it is not clear if the occurrence of hypertension is higher in type 1 than in type 2 diabetes, in diabetics type 1 the incidence of subjects with hypertension is near 40%. 1 Diabetes mellitus (DM) type 2I is a very frequent illness whose occurrence has increased during the last decades as a consequence of a series of factors; we should mention among them the higher longevity of the population and a progressive increment of obesity and sedentary life. Hypertension in type 2 diabetes mellitus has a negative effect on the velocity of appearance and progression of complications of the disease such as nephropathy and retinopathy.
The risk of fatal and non-fatal cardiovascular
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events in people with DM type 2 is two to four times higher than in non-diabetic patients. If we include other risk factors such as hypertension, hyperlipidaemia, obesity, etc, we observe that the coexistence of these factors with diabetes leads to a multiplying effect of the risks for cardiovascular accidents.
Pathogenesis of arterial hypertension in diabetes
Diabetes mellitus is a chronic disorder with a genetic basis with a high influence from environmental factors with three kinds of characteristic manifestations: (1) a metabolic syndrome consisting of hyperglycaemia, glycosuria, polyphagia, polydipsia, polyuria and alterations of the lipid and protein metabolisms due to a complete or partial deficiency of the action of insulin and/or a peripheral resistance to the insulin effect; (2) a vascular syndrome including (a) macroangiopathic alterations affecting all organs, particularly heart, brain and peripheral circulation, kidney and retina, and (b) a microangiopathic component involving the microcirculation producing mainly endothelial dysfunction; (3) a peripheral or autonomous neuropathic syndrome causing vascular disfunction. 3 It is known that the majority of hypertensive diabetics have type 2 DM, usually without nephropathy. In type 1 DM blood pressure is not altered at the beginning of the illness so that the appearance of hypertension in type 1 DM is related to kidney damage. Although, in both types of diabetes hyperinsulinaemia is present, different mechanisms are proposed for the appearance of hypertension. In the following section we propose several suggested mechanisms trying to explain the vascular problems in diabetics.
The vascular changes described in the subject with hypertension are: increase in thickness of the media in all vessels (large, medium, small and arterioles), as an adaptive response to the increased resistance in the wall of the artery in order to regulate the local blood flow, a phenomenon observed in the circulatory system as a whole, including large vessels and even resistance arterioles what amplifies and perpetuates arterial hypertension. However, in animal models these structural changes show hypertrophy in the large vessels and hyperplasia in small arteries and arterioles. 4 In addition to these mechanic changes, the phenomenon of vascular rarefaction is described, consisting of the effective loss of microvascular perfusion units, arterioles or capillaries, leading to a decrease of blood flow to the skeletal muscle. Insulin resistance is directly related to low perfusion and loss of the capillary bed density in the skeletal muscle. In diabetic subjects structural changes of the vessels walls associated to hyperglycaemia have been described. 5 Today we know that the endothelium mediates the ability of the blood vessels to modify their architecture in response to haemodynamic changes. 5 The normal endothelium reduces the vascular tonus producing relaxation of the vascular wall and inhibiting the growth of the smooth muscle, adhesion and aggregation of platelets and leukocytes and thus preventing thrombosis. It is easy to understand that an alteration of the inhibitory function of the vascular endothelium will lead to vasoconstriction with an increase of the peripheral vascular resistance and a rise of blood pressure, stimulation of the growth of the vascular smooth muscle and elevation of the adhesion and platelet aggregation, altogether leading to thrombogenic accidents.
Many studies demonstrate that nitric oxide (NO) produced by the endothelium largely contributes to this vascular remodelling participating actively as a negative regulator of the proliferation of vascular smooth muscle in response to stimulation. 6 A dysfunctional endothelium loses not only the capacity to regulate vascular tone, but also its anti-thrombotic and anti-aggregation properties for leukocytes and platelets. 7 Thromboxane A2, produced by the platelets, is the most important agent producing vasoconstriction, is increased in diabetics, and the smooth muscle of the vessels has a higher susceptibility to it. Other agents are endothelin-1, a vasoconstrictor stimulated by hyperglycaemia. In these subjects the concentrations of NO are low; this is the reason for the alterations of the endothelium-dependent phenomenon. Among the vasodilating substances prostacycline is an endothelium agent, produced in lower amounts in diabetics and exhibiting a contradictory vasoconstricting action mediated by thromboxane A2. 4 In diabetics NO is blocked by the products of advanced glycosilation in a time-dependent way beginning during the first 2 weeks and reaching a maximum peak within 2 months. In that manner glycosilated haemoglobin reduces the endotheliumdependent relaxation mediated by NO. Diabetic patients show an elevated oxidative stress produc-
Journal of Human Hypertension
ing a larger amount of free radicals that inactivates the NO, and damage the coupling of the vasodilator to the endothelium receptor.
The coexistence of hypertension and diabetes enhances the loss of the endothelium-mediated vasodilation, which could be explained by a lower production of NO or by a decrease of the response to the NO in the vascular smooth muscle. 8 There are several degrees and types of endothelial dysfunction: (1) damage to the Galphai proteins; (2) lower release of NO, prostacyclines and/or endotheliumderived hyperpolarizing factor, (EDHF); (3) increase in the release of endoperoxidases; (4) increase in the production of oxygen reactive species; (5) increase of endotheline 1 (ET-1) production; and (6) decrease of the vascular smooth muscle sensitivity to NO, prostacyclines, and/or EDHF.
Different metabolic pathways related to hyperglycaemia are involved in the higher production of free radicals (anion super-oxyde hydroxyl). However, none of the investigations carried out recently have shown the limits where blood sugar levels are toxic to the vascular system. When endothelial cells are incubated in high glucose concentrations there is a higher production of advanced glycosilated end-products (AGE), that could inactivate NO.
Nitrous oxide inhibits platelets adherence and aggregation, reduces the adherence of monocytes to the endothelium, the proliferation of the vascular smooth muscle and eliminates the capacity of monocytes to oxydize low-density lipoproteins (LDL).
The activation of the renin-angiotensin-aldosterone system also has an important role in the genesis of endothelial dysfunction in hypertensive individuals. Levels of bradykinin and angiotensin II inside the endothelial wall are controlled by the angiotensin-converting-enzyme (ACE). ACE breaks down bradykinin to produce angiotensin II. Bradykinin stimulates the endothelial cell to release vasodilating substances. The action of kinines is maintained in spite of endothelial dysfunction except in very severe arterial injuries. Angiotensin II could be partly responsible for endothelial dysfunction because it induces resistance to the vasodilatory effect of the NO, so that by stopping the production of angiotensin II the direct and indirect vasoconstrictive effects of this peptide are blocked. 9 Another possible contribution of DM to endothelial dysfunction is the impairment of the lipid profile; it has been demonstrated that hypercholesterolaemia accelerates the deficit of intracellular arginine, reducing the activity of the NO synthetase, lowering the production of NO and increasing endothelin secretion predominating the vasoconstrictive response. It is important to remark that the development of the atherosclerotic process begins with an initial injury produced either by a metabolic trauma like diabetes, hypercholesterolaemia, smoking, infections, ischaemia, etc; or by a physical trauma such as hypertension and percutaneous coronary angioplasty. 4 
Insulin and atherosclerosis
There is a relationship between the decrease of sensitivity to the effect of insulin, secondary hyper-insulinism and predisposition to atherosclerosis. High levels of insulin are related to elevated concentrations of plasminogen type I inhibitor (PAI-1), due to an apparent direct effect of insulin on the PAI-1 producing hepatocytes. Therefore, the atherogenic effect of insulin is mediated partly by high levels of PAI-1 with the ensuing inhibition of fibrinolysis. PAI-1 is proportionally related to the triglycerides levels in patients with ischaemic cardiopathy but in addition it is found in high concentrations in the atheromatous lesion. Obese patients with type II DM show high levels of PAI-1 associated with hyperinsulinism and hypertriglyceridaemia.
Resistance to insulin could be defined as a decrease to the response or to the sensitivity of the effectors to the hormone action. Insulin effectors include principally, muscle cells, adipocytes, hepatocytes and also the beta cells of the pancreatic islets. 10 Resistance to insulin could be divided in: (1) decrease of the sensitivity to the hormone (postreceptor failure); (2) decreased biological response to insulin; and (3) decreased sensitivity and response. The immediate results of insulin-resistance is the compensating increment of pancreatic ␤ cell secretion, which leads to hyperinsulinism, with high serum insulin concentrations without hypoglycaemia. 10 Insulin has direct and indirect atherogenic effects. It acts directly as a mitogenic factor for the smooth muscle cells contributing to their proliferation. Additionally it acts as a migratory factor of the smooth muscle cells from the media to the intima. Also it increases the tubular sodium reabsorption in the kidney and the sympathetic activity, all of which could contribute to the development of arterial hypertension. Indirectly, insulin has a large influence in the lipid profile acting on the catabolism of triglyceride-rich lipoproteins increasing the concentration of strongly atherogenic remnants. Insulin participates in different processes of lipid catabolism. So, it is known that a low insulin efficiency leads to a higher amount of strongly atherogenic glycosilated LDL particles, the precursors of the foam cells. Insulin also increases the number and activity of the cell receptors for LDL stimulating the HMGCoA reductase, and regulates the synthesis of intracellular cholesterol. In the high-density lipoprotein (HDL) receptor insulin modulates the lecitin-cholesterol-acil transferase. Hyperinsulinaemia also increases the liver production of very low-density lipoproteins (VLDL), causing hypertriglyceridaemia since insulin resistance reduces the removal of triglycerides. 10 In addition it should be mentioned that hyperinsulinaemia might decrease the levels of dehydroepiandrosterone (DHEA) in men.
Recently it has been established that acute hyperinsulinaemia strongly reduces protein degradation in the myocardium of patients with cardiovascular disease and resistance to the peripheral action of insulin. This kind of antiproteolitic response represents a potential mechanism through which hyperinsulinaemia contributes to the development of myocardial hypertrophy in patients with cardiovascular disorders. 4 Hyperglycaemia, atherosclerosis and diabetes associated vascular complications are linked by another mechanism: the non-enzymatic glycosilation of proteins, which include the serum lipoproteins. Non-enzymatic protein glycosilation is related to several processes promoting atherosclerosis. 11 The binding of glucose to proteins produces insoluble complexes called advanced glycosilated end products (AGE), 12 which are synthesized in higher amounts in hyperglycaemia. The effects of the AGE proteins include the following: (1) procoagulant changes on the surface of endothelial cells and higher oxydative stress due to binding to endothelial cells; (2) a greater endothelium permeability because of inhibition of the association of heparinsulphate to the extracellular matrix; (3) alteration of the endothelium-dependent vasodilation as a result of nitric oxide depletion; (4) proliferation of smooth muscle cells induced by cytokines resulting from binding of AGE-bounded proteins to specific macrophages receptors; (5) a higher secretion of platelet-derived growth factor (PDGF) and a pronounced enhancement of circulating monocytes chemotaxis.
Insulin's theory for hypertension
It was Reaven, who first associated cardiovascular accidents, obesity and intolerance to glucose using the term X Syndrome, called later on Metabolic Syndrome. At present Assmann 13 has proposed the term Metabolic Cardiovascular Syndrome and established defining diagnostic criteria that include: (1) resistance to insulin with hyperinsulinaemia and decreased glucose tolerance; (2) dislipidaemia, hypertriglyceridaemia and decrease of HDL-col; (3) thrombogenicity due to increase of coagulation factor VII and to the inhibitor of the plasminogen activating factor (PAI-1); (4) hypertension with sympathetic hyperactivity; (5) trunk obesity accompanied by increase of free fatty acids (FFA) in the portal vein; (6) hyperuricaemia.
Different direct findings could explain the presence of hypertension in insulin-resistant diabetic patients, such as: (1) increase of sodium and water reabsorption in the proximal renal tubuli increasing the intravascular volume. (2) Activation of the sympathetic nervous system with the ensuing rise in the concentration of catecholamines, leading to an increase of the heart rate, myocardial contractility and cardiac output. It has been reported higher tone of the great veins as well as vasoconstriction of the resistance vessels together with an increment of tubulo-renal sodium reabsorption and renin liberation; 2,4 (3) Alteration of the function of the insulindependent transmembrane ionic pumps, which is expressed in: (a) increase of the sodium-proton pump activity, what causes a great deal of hydrogen ions to leave the cells and rising of intracellular pH. This has an easy vascular reactivity to noradrenaline, angiotensin II and to salt overload and stimulates the cell proliferation of the arteriole smooth muscle; (b) reduction of the activity of the sodiumpotassium-ATPase insulin-dependent pump with the subsequent increase of sodium and decrease of potassium concentrations inside the cell; (c) increased reactivity of smooth muscle due to cito-solic Ca2+ increase as the Ca-ATPase becomes resistant to insulin. (4) Enhancement of arteriolar vasoconstriction because of greater sensitivity to vasoconstrictor and lower sensitivity to vasodilator stimuli. The impairment of the Na-K-ATPase insulin-dependent pump disappears slowly by addition of L-arginine, the precursor for NO. The synthesis of NO is directly correlated to the sensitivity to insulin in healthy patients. 4, 7 Additionally, acute hyperinsulinaemia increases endothelin concentrations so that diabetics show a higher response to noradrenaline and angiotensin II. (5) Activation of insulindependent growth factors (protooncogene e-myc, IGF-1 and IGF-2) producing more hypertrophy of the vessel wall. Recent studies have established that such growth factors have an effect on the glucose transporters of muscle and fat cells causing translocation of the transporter GLUT-4, the main glucose transporter and insulin-dependent situated principally in skeletal muscle, heart and adipocytes. 14 
Abnormalities of lipids
Insulin, a classic anabolic hormone, has a high metabolic activity in the adipose tissue, which promotes the deposit of triglycerides in the adipocytes by different mechanisms: (a) induces the production of lipoprotein lipase, which is bounded to the endothelial vascular cells of the adipose tissue, breaking down the circulating lipoproteins; (b) increases the glucose transport into the fat cell augmenting the use of alpha-glycero-phosphate for the esterification of free fatty acids; (c) inhibits the intracellular lipolisis.
Glycosilation of lipoproteins elevates its atherogenic potential. Glycosilated LDL, not detected by the classic LDL receptors, increases the synthesis of cholesterol esters and the accumulation of macrophages. The formation of foam cells through capturing of lipids by macrophages as well as cell proliferation in the smooth muscle is higher when glycosilated LDL bind to the macrophage receptors. 11 In 1988 Randle et al 15 proposed that the increase of the free fatty acid oxidation limits the glucose consumption in the muscle due to alteration of the oxidation-reduction potential of the cell and to the inhibition of many glycolisis enzymes. When large amounts of fatty acids are oxidized acetylCoA accumulates in the cell, a powerful inhibitor of the pyruvate dehydrogenase complex. This complex is activated when pyruvate is being used for the formation of acetyl-CoA. The activation is produced by dephosphorylation of the inactive form of the enzyme catalysed by the pyruvate phosphatase I and II, which at the same time are stimulated by the Ca2+ and Mg2+ levels of the cell and by the binding of insulin to its receptors. The results of these biochemical disorders include the inhibition of insulininduced glucose processing increasing the free fatty acid concentration and promoting in that way oxidation of fats. 10 The consequence of all these biochemical phenomena is a decrease of the synthesis and activity of the adipocyte lipoprotein lipase (LPL)
Journal of Human Hypertension since insulin acts as its major regulator and increases the activity of the liver lipase, which accelerates the synthesis and secretion of hepatic VLDL rich in triglycerides, 16 producing hypertriglyceridaemia, reduction of HDL-cholesterol, changes in the composition of the LDL generating dense and short LDL particles and accumulation of VLDL remnants and chylomycrons, all of these factors contributing to the genesis and persistence of hypertension in the diabetic patient.
Pharmacological treatment
The high rate of patients with DM forces us upon maintaining an adequate level of metabolic control and reduction of other cardiovascular risk factors such as the lipid profile, arterial hypertension and tobacco habits. This is the case of patients presenting DM and hypertension, two morbid conditions that together are present in 50% of patients with type 1 and type 2 diabetes mellitus. It is known that cardiovascular diseases are present in 75% of all deaths associated with DM. 17 Diabetes mellitus and hypertension are closely related and predispose the individual to arteriosclerosis and kidney failure.
The object of blood pressure control in diabetic patients is to reduce as much as possible the number of deaths and disabled people. The optimal level of blood pressure in diabetic patients is still not established but the statements of the VI JNC show that 130/85 mm Hg should be the values searched for. 18 The efficiency of a hypertension treatment should be measured not only by the reduction of blood pressure but also by a lower excretion rate of urinary albumin, the nephroprotective effect. The choice of an antihypertensive drug ought to be based not only on the reduction of blood pressure alone but also on a better control of glycaemia, lipid profile and thrombotic disorders. 19 According to the literature control of blood pressure must be sufficient in order to reduce the velocity and the extent of damage to kidney function. Among the different antihypertensive drugs, the inhibitors of the angiotensin-converting-enzyme (ACEI) are recommended by the VI JNC. The ACEI delay the progression of microalbuminuria and could reduce the percentage of patients showing terminal renal failure. Comparative studies between ACEI and calcium channel blockers such as the Appropriate Blood Pressure Control in Diabetes (ABCD), in which enalapril was compared with nisoldipine, a calcium channel blocker with long half-life, demonstrating after 5 years that cardiac infarction was significantly reduced in the group treated with enalapril. In another study using fosinopril and amlodipine, the Fosinopril and Amlodipine Cardiac Events Trial (FACET) proved that cardiacaccidents were duplicated in patients treated with calcium channel blockers, but blood pressure was higher using ACEI. 18, 20 This study suggested also that the combined use of calcium channel blockers and an ACE inhibitor was effective in the treatment of hypertension, as supported by the findings of the Systolic Hypertension meeting in Europe (SystEur). 21 More recently, the study Hypertension Optimal Treatment (HOT) also demonstrated that the combined use of calcium channel antagonists with ACEI make a rational therapeutic choice for patients presenting hypertension and diabetes. 22 Other studies have established that the kidneys of type 2 diabetics were structurally heterogeneous with less than one-third of them showing typical changes of diabetic nephropathy a decrease of kidney function only in those patients with typical structural changes. 23 Additional comparative studies with ACEI and beta-blockers, such as the United Kingdom Prospective Diabetes Study (UKPDS), found no difference in the rate of cardiovascular or diabetic complications, not even in the microalbuminuria or proteinuria in patients treated with captopril or atenolol, and they conclude that both drugs are equally effective and safe, and could be used with great benefit for the treatment of uncomplicated hypertensive type 2 diabetic patients. 19, 24 Other studies show improvement of retinal arterial and brain blood flow with the use of ACEI (perindopril 4 mg) compared with atenolol. 25 When using the ACEI there are studies showing fosinopril as one of the most adequate for its double elimination route simplifying the use in patients with nephropathy. 26 Nevertheless other authors prefer the use of quinalapril since it could attenuate endothelial dysfunction in coronary disease, not only for the inhibitory effect of the ACEI upon the formation of angiotensin II but because of its capacity to prevent bradykinin degradation. 7 In the group of calcium channel blockers there also exists the possibility of treatment with the nondihydropyridine calcium antagonists verapamil and diltiazem that also decreases the excretion of albumin and proteins and apparently improves insulin sensitivity. 1 It is reported in some studies the use of candersartan and cilexetil (angiotensin II receptor antagonist) specific for AT1 receptors; these had no effect on the homeostasis of glucose and serum lipids when used in hypertensive patients and type 2 diabetics showing a fairly good control of their blood pressure values and a well tolerated. 27 Diet, exercise, insulin and oral antidiabetic drugs have been the most important resources for the treatment of uncomplicated diabetes. At present when an oral antidiabetic drug is required, the tendency is to choose second generation sulphonilurea (gliburide or gliclazida). 28 The therapeutic system glipizida GITS is a valid alternative.
During the treatment of the diabetic patient with arterial hypertension, a good control of the blood sugar reduces considerably the onset of new complications caused by the two processes that work on the altered endothelium. Glicazide returns the lipid peroxides and the activity of mononuclear cells to normal levels, 29 and reducing the levels of platelet aggregation 30 have a proven action on the cardiovascular system of diabetic patients, when they are compared with other sulfonilureas. Even more, it shows antioxidant actions compared with those of the vitamin E.
There are other drugs such as the thiazolindinediones (Troglitazone) that does not only have an improving effect in the peripheral sensitivity to insulin but also in improving lipid profile, it does not affect insulin secretion and blocks the release of ␣-tumor-necrosis-factor and produces vasodilation by blocking calcium movement. 31, 32 Other possibilities of new antihypertensive drugs could be Urapidil, a postsynaptic and peripheral alpha-1 antagonist with central agonist effect on the serotoninergic 5-HT1A receptors that does not affect glucose and lipid metabolism. 33 Likewise, the hypolipidic treatment with statins and aspirin have been shown to be effective and promise a better prognosis for diabetic patients with cardiovascular disease. The efficacy of aspirin at low dose (81-325 mg/day), was demonstrated by the Anti-Platelet Trialists (APT), in which a reduction of vascular accidents in diabetic and non-diabetic patients was observed, corroborated by the Early Treatment Diabetic Retinopathy Study (ETDRS). 34, 35 
